7.97
-0.01 (-0.13%)
| Previous Close | 7.98 |
| Open | 7.96 |
| Volume | 899,098 |
| Avg. Volume (3M) | 1,460,521 |
| Market Cap | 658,103,744 |
| Price / Book | 1.08 |
| 52 Weeks Range | |
| Earnings Date | 3 Feb 2026 |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 7.95 |
| Operating Cash Flow (TTM) | -192.25 M |
| Levered Free Cash Flow (TTM) | -110.31 M |
| Return on Assets (TTM) | -31.26% |
| Return on Equity (TTM) | -62.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Replimune Group, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.30 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 107.50% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 19.00 (Wedbush, 138.39%) | Buy |
| Median | 16.50 (107.03%) | |
| Low | 14.00 (Piper Sandler, 75.66%) | Buy |
| Average | 16.50 (107.03%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.97 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 05 Feb 2026 | 14.00 (75.66%) | Buy | 6.93 |
| Wedbush | 04 Feb 2026 | 19.00 (138.39%) | Buy | 7.00 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ASTLEY-SPARKE PHILIP | - | 8.04 | -25,000 | -201,000 |
| Aggregate Net Quantity | -25,000 | |||
| Aggregate Net Value ($) | -201,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 8.04 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ASTLEY-SPARKE PHILIP | Director | 18 Feb 2026 | Disposed (-) | 25,000 | 8.04 | 201,000 |
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update |
| 18 Dec 2025 | Announcement | Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |